NCT01614457View on ClinicalTrials.gov

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Cystic Fibrosis

Interventions

DRUG

Ivacaftor

Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.

DRUG

Placebo

Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.

Trial Locations (31)

Unknown

Birmingham

Palo Alto

Hartford

Tampa

Chicago

Iowa City

Lexington

Baltimore

Boston

Detroit

Grand Rapids

St Louis

Omaha

New York

Syracuse

Valhalla

Chapel Hill

Philadelphia

Pittsburgh

Charleston

Nashville

Dallas

Fort Worth

Houston

Salt Lake City

Richmond

Seattle

Morgantown

Madison

Belfast

Edinburgh

All Listed Sponsors

collaborator

Cystic Fibrosis Foundation

OTHER

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT01614457 - Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) | Biotech Hunter | Biotech Hunter